Natural Capsules Preferential Issue (13 Nov 2026)
Natural Capsules Limited approves Q2 FY27 financials and preferential allotment
Natural Capsules · Pharmaceuticals & Biotechnology
Key highlights
- Board approved unaudited standalone and consolidated Q2 & H1 FY27 financial results on Nov 13, 2026
- Preferential allotment of 1,12,500 equity shares at ₹178 each totaling ₹2.00 crore to promoter Mr. Sunil L Mundra
- Allotment of 4,50,000 fully convertible warrants at ₹178 per warrant, aggregating ₹8.01 crore, also to promoter
Original filing
Unaudited Consolidated And Standalone Financial Results For The Quarter & Half Yearly Ended September 30, 2026.
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Natural Capsules
- Fundraise / allotmentNatural Capsules Ltd announces Q2 FY27 results and approves preferential allotment
- Fundraise / allotmentNatural Capsules Limited approves Q2 2026 results and preferential allotment
Other financial results filings this fortnight
- Financial resultsArvaya HealthcareArvaya Healthcare Ltd announces Q2 FY2026-27 financials, rights issue, and acquisition
- Financial resultsJindal PhotoJindal Photo Ltd files unaudited financial results and reports voluntary delisting
- Financial resultsGSP Crop ScienceGSP Crop Science Limited announces financial results and corporate updates for H1 FY 2026-27
- Financial resultsA-One Steels IndiaA-One Steels India Limited announces unaudited Q2 and half-year financial results for 2026
- Financial resultsCapitalNumbers InfotechCapitalNumbers Infotech Limited announces unaudited H1 FY2026 financial results
- Financial resultsGlobal Vectra HelicorpGlobal Vectra Helicorp Limited files unaudited results for Q2 & H1 ended Sept 2026
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.